[High dosage and intermediate dosage cytosine arabinoside in the treatment of secondary leukemias].
Patients with secondary acute myeloid leukaemia (AML) following treatment with alkylating agents and/or radiation show a poor response to standard induction therapy. Between 1983-1987 8 consecutive patients were treated with high-dose cytosine arabinoside (HD-ARA C; 3 g/sqm twice daily for 6 days) or intermediate-dose cytosine arabinoside (ID-ARA C; 0.5 g/sqm twice daily for 6 days). Complete remission was achieved in 3 patients (HD-ARA C: 2/3l; ID-ARA C: 1/5) and partial remission in 3 patients (ID-ARA C: 3/5). One patient (HD-ARA C) died during prolonged aplasia, one patient (ID-ARA C) proved refractory to treatment. The respective duration of remission in the 3 responsive patients was 3, 7 and 8 months. The probability of survival of the whole group was 50% after 12 months and 25% after 24 months. Our results confirm the efficacy of monotherapy with ARA C in the treatment of secondary AML. Consolidation therapy with ID-ARA C for 4 days seems to prolong remission.
Leitha
T
T
Abteilung für Hämatologie und Blutgerinnung, I. Medizinische Universitätsklinik, Wien.
Jäger
U
U
Schwarzinger
I
I
Bettelheim
P
P
Hinterberger
W
W
Neumann
E
E
Korninger
C
C
Kyrle
P A
PA
Haas
O
O
Schlappack
O
O
D000328:Adult; D000477:Alkylating Agents / Q000009:adverse effects*; D003561:Cytarabine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000188:drug therapy; D007953:Leukemia, Radiation-Induced / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D000477:Alkylating Agents; D003561:Cytarabine
Hochdosiertes und mittelhochdosiertes Cytosinarabinosid zur Behandlung von sekundären Leukämien.